Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Imatinib, 50 mg  

Imatinib, 50 mg

4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate

Synonyms: Gleevec TM, Glivec TM, STI-571
specific inhibitor of Bcr-Abl tyrosine kinase

More details

PKI-IMTB-050

Availability: on stock

750,00 €

Background: Imatinib, formerly referred to as STI571, is a specific ATP competitive inhibitor of Bcr-Abl tyrosine kinase (IC50 = 0.25 µM) and at present the first-choice treatment for patients with chronic myeloid leukaemia (CML). However, some patients show resistance to imatinib either due to point mutations in the Abl kinase domain or because of genomic amplification of bcr-abl. Other therapeutic targets for imatinib mesylate are c-KIT or platelet-derived growth factor receptor (PDGFR) that are expressed constitutively in gastrointestinal stromal tumors (GISTs), whereas inhibitory activity against other kinases (EGFR, INS-R, IGF-R and JAK2) is at least 100-fold lower.

Chemical formula: C29H31N7O. CH3SO3H
Molecular weight: 589.7 g/mol
Purity: >99.0% (HPLC)
Appearance: off white solid
Solubility: soluble in DMSO and aqueous buffers < pH 5.5, but very slightly soluble to insoluble in neutral/alkaline aqueous buffers
CAS number: 220127-57-1

Please note: Imatinib is subject to various patent applications and is intended for research use only. It might not be available in some countries and might not be available to some institutions. Gleevec TM and Glivec TM are registered trade marks of Novartis AG (Switzerland).

Product specific literature references:

van Oosterom AT, Judson I, Nielsen OS (2001) "Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study" Lancet 358(9291):1421-3

Demetri GD, von Mehren M, Joensuu H et al(2002) "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors" N Engl J Med. 347(7):472-80

Talpaz M, Silver RT, Sawyers CL et al (2002) "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study" Blood 99(6):1928-37

Apperley JF, Gardembas M, Goldman JM et al. (2002) "Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta" N Engl J Med. 347(7):481-7

Shah NP, Nicoll JM, Sawyers CL et al (2002) "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia" Cancer Cell 2(2):117-25

Nagar B, Bornmann WG, Kuriyan J et al(2002) "Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)" Cancer Res. 62(15):4236-43

Rubin BP, Schuetze SM, Bruckner JD et al (2002) "Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans" J Clin Oncol. 20(17):3586-91

Sawyers CL, Hochhaus A, Druker BJ et al. (2002) "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study" Blood 99(10):3530-9

Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) "Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug" Nat Rev Drug Discov. 1(7):493-502

O\'Brien SG, Guilhot F, Druker BJ (2003) "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia" N Engl J Med. 348(11):994-1004

Heinrich MC, Corless CL, Fletcher JA et al.(2003) "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor" J Clin Oncol. 21(23):4342-9

Cools J, DeAngelo DJ, Gilliland DG et al. (2003) "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome" N Engl J Med. 348(13):1201-14

Verweij J, Casali PG, Judson I et al. (2004) "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial" Lancet 364(9440):1127-34

Debiec-Rychter M, Dumez H, van Oosterom AT (2004) "Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group" Eur J Cancer 40(5):689-95

Meco D, Riccardi A, Dominici C et al. (2005) "Antitumor activity of imatinib mesylate in neuroblastoma xenografts" Cancer Lett

Heinrich MC, Blanke CD, Druker BJ, Corless CL. (2002) "Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies." J Clin Oncol.  20:1692-1703
Buchdunger E, Matter A, Druker BJ. (2001) "Bcr-Abl inhibition as a modality of CML therapeutics. " Biochim Biophys Acta.1551(1):M11-8

Ramirez P, DiPersio JF. (2008) "Therapy options in imatinib failures." Oncologist. 13(4):424-34.

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.